Takeda's Edarbi set to be gold standard for hypertension

Based on clinical data and the opinions of interviewed thought leaders, Edarbi (azilsartan
medoxomil), from Japan’s largest drugmaker Takeda Pharmaceuticals (TYO: 4502), has earned advisory firm Decision Resources’ proprietary clinical gold standard status for the treatment of hypertension, owing to its strongest clinical profile among key marketed products for the indication.

Through 2020, Decision Resources does not expect any therapy in development to replace Edarbi as the clinical gold standard. While some emerging therapies hold promise, they have efficacy, safety and tolerability, and/or delivery features that prevent them from displacing Edarbi.

Decision Resources’ analysis of the hypertension drug market also finds that surveyed US primary care physicians (PCPs) and managed care organization (MCO) pharmacy directors agree that the reduction of systolic blood pressure is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in hypertension.